Physician profile
Ted Vellos
NPI 1497173447
$3,670.63
in general payments reported to CMS, 2019-2025
50 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.83 · 2020: $241 · 2021: $622 · 2022: $653 · 2023: $504 · 2024: $767 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.29 |
| Education | $135.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $634.70 | 2020-2024 | Xtandi |
| Boston Scientific Corporation | $268.32 | 2020-2025 | Spaceoar Vue System - 10ml |
| Myriad Genetic Laboratories, INC. | $250.32 | 2021-2025 | Prolaris, Myrisk |
| Olympus America INC. | $176.40 | 2019-2025 | Itind System, Soltive, Soltive |
| Coloplast Corp | $172.79 | 2022-2025 | Coloplast Tfl Drive |
| Urogen Pharma, INC. | $126.23 | 2021-2025 | |
| Janssen Biotech, INC. | $126.08 | 2022-2025 | Erleada |
| Teleflex LLC | $109.26 | 2021-2025 | Urolift |
| Endo USA, INC. | $103.19 | 2025 | Aveed, Xiaflex |
| Myovant Sciences INC. | $99.90 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $99.02 | 2020-2024 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $97.49 | 2022-2025 | Keytruda |
| Antares Pharma, INC. | $96.70 | 2021-2025 | Xyosted |
| Dendreon Pharmaceuticals LLC | $96.09 | 2022-2024 | Provenge |
| Tolmar, INC. | $90.08 | 2023-2025 | Jatenzo |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Vellos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.